The FDA converted the PARP inhibitor's 2020 accelerated approval to full approved based on results from the Phase III TRITON3 trial.

While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...

The grant will fund preclinical studies of the dCK inhibitor TRE-515 with KRAS inhibitors in mice, which will then inform the design of clinical trials.

The firm's Phase I/II study yielded responses in mCRPC patients with androgen receptor mutations but it wasn't as promising in HR-positive breast cancer.

Findings from two clinical trials suggest Novartis' Itvisma is safe and effective for SMA patients over two years old.

The UC Berkeley spin-out aims to develop one-time treatments for chronic and rare diseases using an RNA- and LNP-based platform.

The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...